Volume 10, Issue 6

ETI (CFTR Triple Therapy): Clinical Opportunities

In this issue:

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? 

Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. 

Learning objectives:

  • Describe the new evidence supporting the indications for triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in patients with F508del and a gating/residual function mutation. 
  • Discuss advice for patients on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI) who become pregnant and plan to breastfeed.  

Author:

Edward McKone, MD
Edward McKone, MD

Clinical Professor
St. Vincent’s University Hospital and University College Dublin School of Medicine
National Referral Center for Adult Cystic Fibrosis
St. Vincent’s University Hospital and University College Dublin School of Medicine
Dublin, Ireland

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse 
Pediatric Clinic Coordinator 
Johns Hopkins Cystic Fibrosis Center 
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: September 14, 2022
Expiration date: September 13, 2024